Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.

NCT01026701 · clinicaltrials.gov ↗

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: bortezomib

Sponsor

Janssen Korea, Ltd., Korea